ReviewMammalian cell display technology coupling with AID induced SHM in vitro: An ideal approach to the production of therapeutic antibodies

- Traditional antibody technology may not produce ideal therapeutic antibodies.
- Mammalian cell display technology can produce full-length all human antibodies.
- In vitro SHM technology is vital for high affinity antibodies production.

Traditional antibody production technology within non-mammalian cell expression systems has shown many unsatisfactory properties for the development of therapeutic antibodies. Nevertheless, mammalian cell display technology reaps the benefits of producing full-length all human antibodies. Together with the developed cytidine deaminase induced in vitro somatic hypermutation technology, mammalian cell display technology provides the opportunity to produce high affinity antibodies that might be ideal for therapeutic application. This review was concentrated on the development of the mammalian cell display technology as well as the activation-induced cytidine deaminase induced in vitro somatic hypermutation technology and their applications for the production of therapeutic antibodies.

Mimicking in vivo antibody production process.